The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The company’s Growth Portfolio delivered $6.2 billion in revenue
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated
